Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy DOI
Qing Nian,

Yan Lin,

Jinhao Zeng

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 52, P. 102237 - 102237

Published: Dec. 12, 2024

Language: Английский

Global, regional, and national childhood brain and central nervous system cancer burden: An analysis based on the Global Burden of Disease Study DOI Creative Commons

Zhenjin Su,

Jie Lu, Yuheng Shi

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Abstract Objectives We assessed the global, regional, and national burden of childhood brain central nervous system cancer from 1990 to 2021 (the latest year). Methods utilized data Global Burden Disease Study, we analyzed trends in through joinpoint regression. global various perspectives. Lastly, The Bayesian age-period-cohort model was employed forecast future 2030 Results Childhood CNS cancers are most common solid tumors leading cause death children. From 2021, age-standardized incidence, prevalence, mortality, DALYs have shown a decreasing trend. incidence is slightly higher boys than girls peaking at ages 0–4 years, with age. disease correlates socio-demographic indices, burdens observed regions indices. Future projections indicate continued decline DALYs. Conclusions While has significantly decreased due medical advancements, it continues be major mortality. Further optimization health resources crucial alleviating this burden.

Language: Английский

Citations

0
A critical review of RAF inhibitors in BRAF-mutated glioma treatment DOI
J. Khoury, Sophie Wehbe, Fouad Attieh

et al.

Pharmacogenomics, Journal Year: 2024, Volume and Issue: 25(7), P. 343 - 355

Published: May 2, 2024

BRAF gliomas have garnered significant attention in research due to the lack of effective treatments and their notable incidence, constituting 3% all gliomas. This underlines importance investigating this area impact that targeted therapies could hold. review discusses development for these tumors, examining effectiveness first-generation inhibitors such as Vemurafenib, Dabrafenib Encorafenib, while addressing challenges posed by paradoxical ERK activation. The advent pan-RAF inhibitors, notably Tovorafenib, offers a promising advance, demonstrating enhanced efficacy better penetration blood–brain barrier, without issue Nevertheless, continued is essential refine therapeutic strategies BRAF-mutated gliomas, given evolving nature therapy development.

Language: Английский

Citations

1
Emerging and Biological Concepts in Pediatric High-Grade Gliomas DOI Creative Commons

Abigail Yoel,

Shazia Adjumain,

Yuqing Liang

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(17), P. 1492 - 1492

Published: Sept. 5, 2024

Primary central nervous system tumors are the most frequent solid in children, accounting for over 40% of all childhood brain tumor deaths, specifically high-grade gliomas. Compared with pediatric low-grade gliomas (pLGGs), (pHGGs) have an abysmal survival rate. The WHO CNS classification identifies four subtypes pHGGs, including Grade 4 Diffuse midline glioma H3K27-altered, hemispheric H3-G34-mutant, pediatric-type H3-wildtype and IDH-wildtype, infant-type In recent years, we seen promising advancements treatment strategies gliomas, immunotherapy, CAR-T cell therapy, vaccine approaches, which currently undergoing clinical trials. These therapies underscored by integration molecular features that further stratify HGG subtypes. Herein, will discuss evolving landscape treating these challenging tumors.

Language: Английский

Citations

1
Multifaceted functions of the Wilms tumor 1 protein: From its expression in various malignancies to targeted therapy DOI
Qing Nian,

Yan Lin,

Jinhao Zeng

et al.

Translational Oncology, Journal Year: 2024, Volume and Issue: 52, P. 102237 - 102237

Published: Dec. 12, 2024

Language: Английский

Citations

0